Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)

INTRODUCTION: PF-06438179, a potential biosimilar to Remicade(®) (infliximab, Janssen Biotech, Inc.), is a chimeric mouse–human monoclonal antibody targeting human tumor necrosis factor alpha (TNF). METHODS: Analytical (small subset reported here) and nonclinical studies compared the structural, fun...

Full description

Saved in:
Bibliographic Details
Published in:Adv Ther
Main Authors: Derzi, Mazin, Johnson, Theodore R., Shoieb, Ahmed M., Conlon, Hugh D., Sharpe, Penny, Saati, Andrew, Koob, Sarah, Bolt, Michael W., Lorello, Leslie G., McNally, Jim, Kirchhoff, Carol F., Smolarek, Teresa A., Leach, Michael W.
Format: Artigo
Language:Inglês
Published: Springer Healthcare 2016
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5083783/
https://ncbi.nlm.nih.gov/pubmed/27585978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-016-0403-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items